On the public citation graph

Clinical Trial Evidence Supporting Fda Approval of Orphan Products between 2017 to 2023

0 signed · 14 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jama.2013.282034openalex-extracted
Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents, 2005-2012
inferredcites →https://doi.org/10.1001/jama.2014.3401openalex-extracted
Trial Evidence and Approval of Therapeutic Agents
inferredcites →https://doi.org/10.1001/jamaoncol.2018.3498openalex-extracted
Orphan Cancer Drugs in the Era of Precision Medicine
inferredcites →https://doi.org/10.1002/ana.21676openalex-extracted
Pivotal studies of orphan drugs approved for neurological diseases
inferredcites →https://doi.org/10.1016/s2214-109x(24)00056-1openalex-extracted
The landscape for rare diseases in 2024
inferredcites →https://doi.org/10.1038/nrd3275openalex-extracted
Rare diseases, orphan drugs and their regulation: questions and misconceptions
inferredcites →https://doi.org/10.1038/s41573-019-0049-9openalex-extracted
Therapies for rare diseases: therapeutic modalities, progress and challenges ahead
inferredcites →https://doi.org/10.1038/s41588-022-01027-wopenalex-extracted
A call for an integrated approach to improve efficiency, equity and sustainability in rare disease research in the United States
inferredcites →https://doi.org/10.1056/nejmp2104846openalex-extracted
“Dangling” Accelerated Approvals in Oncology
inferredcites →https://doi.org/10.1111/j.1440-1681.1998.tb02179.xopenalex-extracted
MULTIPLE COMPARISON PROCEDURES UPDATED
inferredcites →https://doi.org/10.1136/bmj-2022-073242openalex-extracted
FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis
inferredcites →https://doi.org/10.1136/bmj.h4679openalex-extracted
Characteristics of efficacy evidence supporting approval of supplemental indications for prescription drugs in United States, 2005-14: systematic review
inferredcites →https://doi.org/10.1186/s13023-014-0170-0openalex-extracted
A comparison of interventional clinical trials in rare versus non-rare diseases: an analysis of ClinicalTrials.gov
inferredcites →https://doi.org/10.2471/blt.23.289731openalex-extracted
Uptake of orphan drugs in the WHO essential medicines lists
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.